Drugs / CART-19 cells
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05270772 | Feb 2021 → Jul 2022 | B-cell acute lymphoblastic leukemia | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02924753 | Jul 2016 → Jul 2019 | B-cell acute lymphoblastic leukemia | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02081937 | Mar 2014 → Dec 2018 | mantle cell lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02794246 | Jun 2016 → Feb 2019 | plasma cell myeloma | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03391739 | Jan 2016 → Dec 2019 | precursor B-cell acute lymphoblastic leukemia | Fujian Medical University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01864889 | Apr 2013 → Apr 2017 | B-cell adult acute lymphocytic leukemia, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma +1 | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T-19 Cells | “the anti-CD19 (cluster of differentiation antigen 19 ) vector (referred to as CART-19 cells)” NCT01864889 ↗5“vector (referred to as CART-19 cells).” NCT02081937 ↗ |
| Modality | Cell therapy | “genetically engineered lymphocyte therapy” NCT01864889 ↗ |
| Target | CD19 | “CAR targeting the B-cell antigen CD19” PMID 26451310 ↗ May 2015 |